The Secret to Making Money from Bioscience's "Scariest Event"
In bioscience investing, binary catalysts are milestone events that signal a thumbs-up or thumbs- down for an experimental drug as it makes its way through the regulatory process.
Positive catalysts can send a share price soaring. Negative ones can send it into a nosedive.
Perhaps the least understood of these catalysts are FDA Advisory Committee (a.k.a. AdCom) recommendations.
But they're also among the most powerful.
Here's what I mean, and how to play them profitably... Full StoryRead More...
Seven Biotech Stocks to Watch Based on "Game-Changing" Cancer Treatment Updates
A number of promising cancer treatments were presented this week by key global pharmaceutical players at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) - which is why this is a key time of year to watch a specific group of biotech stocks.
The event, which this year took place May 30 - June 3, is attended by thousands of renowned oncologists, researchers, analysts, and investors. It is unquestionably the most highly anticipated and most news-generating cancer research meeting of the year.
ASCO can deliver a blockbuster, breakout drug that will not only lead to better cancer treatments, but one that will also bring in billions of dollars in revenue. Moreover, there's also the potential of a drug's developer becoming a profitable takeover target.Check out this list of biotech stocks to watch post-ASCO.
The Four Telltale Signs of a Bioscience "Blockbuster" in the Making
The FDA's Expedited Programs help get promising new therapies for seriously ill patients approved as soon as possible.
But they also create an unintended side effect that's a huge advantage for investors: They point exactly to the biggest money-making opportunities in the bioscience industry.
They're like big, green, neon signs that say, "This is an important drug with incredible profit potential."
And this is how you find them... Full StoryRead More...
Why Tesaro (Nasdaq: TSRO) Stock Is Surging Today
Shares of Tesaro Inc. (Nasdaq: TSRO) stock were up 23% today (Monday) after the company announced that its drug rolapitant met the main goal of its third and final Phase 3 trial.
According to Money Morning's BioScience Investment Specialist Ernie Tremblay, volatility like that of TSRO stock is common among biotech companies with late stage drug candidates.Here's what investors should expect from this hot biotech stock now...
Best Stocks to Buy Now: A Hot Biopharma, an Energy Sector Worth $2 Trillion, and More
Our roundup of the best stocks to buy last week gave Money Morning Members more than a dozen plays in 2014's most profitable sectors.
One pick involves a possible healthcare merger that would combine two industry titans. The duo would create an industry powerhouse with a market cap near $300 billion. Another play revolves around one of the most highly anticipated, and possibly biggest, initial public offerings ever. And a special report from our small-cap trading specialist showed readers a technique for uncovering investment winners today.Here they are – with more opportunities – in our latest Money Morning best stocks to buy list:
Stocks to Buy: Why This Biopharma Company Is a “Long-Term Profit Machine”
One strategy experts use when looking for the best biotech stocks to buy is finding companies with promising drug candidates that are close to receiving regulatory approval. When these drugs hit the market, they can bring in billions in revenue.
When companies have multiple promising drugs in their product pipeline, they become even more attractive because they have more than one shot at finding a revenue blockbuster.That’s why Money Morning’s Defense & Tech Specialist Michael A. Robinson likes this biotech stock to buy now…
Stocks to Buy: This Botox Competitor Is Heading Toward Huge Profits
When Valeant Pharmaceuticals International Inc. (NYSE: VRX) and activist investor Bill Ackman made an unsolicited $46 billion bid to purchase Botox maker Allergan Inc. (NYSE: AGN) last week, investors got a glimpse of just how big the Botox market is globally.
And that had us pointing to our "Stocks to Buy" list...Money Morning's Defense & Tech Specialist Michael A. Robinson has been recommending a biotech stock that develops similar specialty products for dermatological applications. And it could see huge gains soon...
Stocks to Buy: 95% Return Is Just the Start For This Biotech Play
Investors looking for stocks to buy in 2014 have had an abundance of new options as 94 companies have gone public this year, according to Renaissance Capital.
The average return for those 94 companies since their IPO date is 9%. But some stocks have far outpaced the average, and are still at great buy-in points even after huge gains.Money Morning's Defense and Tech Specialist Michael Robinson has found a stock that still provides investors a great profit opportunity, even after posting a 95% return from its IPO date...
These Long-Term Profit Machines Just Went On Sale
Market volatility has suddenly created some great opportunities, including those in the biotech sector.
Supporting the inevitable ascent of the industry is the release of a steady stream of compounds that have helped them rack up billions in new revenue.Grab these long-term profit machines at a discount now.
Three Orphan Drug Stocks to Buy When the Biotech Market Is Down
There's no sugarcoating it: Biotech stocks have had a rough run in the past month.
But when other investors are running for the hills, Money Morning experts are finding profit plays. With biotech stocks trading lower, there are excellent buy-in opportunities on valuable biotech companies.
Orphan drugs offer some of the best profit plays in biotech as the have extremely lucrative markets cornered.And these three stocks to buy are the best orphan drug plays now...
There Is No Biotech Bubble; Here's the Real Story
Some analysts feel that the biotech sector's recent tumble is evidence of the biotech bubble bursting.But they're wrong; the market is simply in a period of adjustment.
The premise behind the bubble idea is that biotech companies as a group are overvalued, that their market caps aren't supported by performance. In other words, that their perceived value is all smoke and mirrors.The problem with that argument is, these analysts are using a mass of technical indicators to support it. Anyone who's followed start-up biotechs knows that's a fool's errand.
- Finding the Blockbuster That Will Make You Rich In the pharmaceutical industry, a "blockbuster" is any drug that brings in $1 billion or more in revenue per year. It's the prize that every biotech hopes to win - and every biotech investor hopes to cash in on. So how do you spot one in the making? If the market suspects a drug candidate has blockbuster potential, catalysts (events like positive clinical study results and regulatory milestones) will give its manufacturer's share price a big, big boost. There is no crystal ball that's 100% accurate when experimental drugs are concerned, but here are some telling questions that can narrow your search... Full story...
The Secret Behind This Controversial Industry's Leader
As a long-time tech-investing analyst, I have one of the best vantage points in the country for tracking profitable marijuana industry trends.
Here's the thing: I live 10 minutes from the epicenter of the medical marijuana movement in northern California, and the rest of the nation for that matter.
Downtown Oakland contains a small cannabis-friendly district known as "Oaksterdam." In fact, there's a patient co-op across the street from a store where I buy my fedoras.
I bring all this up so you know I've followed what's been happening with the marijuana legalization movement for years.
In these parts, it's difficult to avoid - you see lots of folks walking around wearing their official Oaksterdam t-shirts.
Since California legalized medical marijuana in 1996, another 19 states have joined the movement.
The San Francisco-based market research firm ArcView Group estimates the national legal marijuana market at $1.53 billion in 2013. ArcView expects sales to nearly double to $2.57 billion by the end of this year.Read More...
One Stock, 18 Ways to Make Big Money
To be worth an investor's money, any promising pre-profit biotech needs to offer high scores on three fundamental benchmarks: pipeline depth, lead product quality, and cash-reserve to burn ratio.
Very few young pharma firms meet these qualifications, of course.
That's what makes a company like this so exciting... Full Story
Double Your Money with Our "High-Tech GPS"
Early last year, I saw a research study that said nearly 60% of all U.S. workers have a net worth of less than $25,000.
And that means they have no retirement.
From the moment that I saw that research, I knew I had a mission - to help folks reclaim their financial futures by breaking free of Wall Street's self-serving shackles... and creating wealth all on their own.
And I knew there was one avenue to travel - the high-tech highway.
So I developed a roadmap - a set of five rules - that would serve as a kind of "tech-investing GPS." My goal was to help investors identify "double-your-money" tech stocks - and navigate their way to massive high-tech wealth.
Today I'm going to walk you through those rules again, and also give you a bonus - a biotech stock with double-your-money potential.So let's get started...